ISSN: 1859 - 2872
Changes in serum levels of anti-SARS-CoV-2 IgG antibody after vaccination for COVID-19 at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: To investigate the change of anti-SARS-CoV-2 IgG antibody levels in individuals after vaccination with AstraZeneca, Moderna, and Pfizer vaccines. Subject and method: 221 adult volunteers received two shots of the same vaccine from Astra-Zeneca (n = 92), Moderna (n = 41) or Pfizer (n = 88) at 108 Military Central Hospital during the period from 11/2021 to 2/2022 according to the injection procedure of the Ministry of Health. Serum levels of SARS-CoV-2 IgG antibodies after the second injection were quantified by automated chemiluminescence immunoassay on a DXI800 machine (Beckman Coulter, USA). Appropriate statistical and comparative analysis techniques were used to assess changes in antibody concentrations over time and to compare post-injection antibody concentrations at different time points between vaccine types. Result: During the peak of the COVID-19 pandemic, from November 2021 to February 2022, the post-injection infection rate was significantly lower (1.3%) than that observed after the first dose (4.5%) and before injection (6.3%). IgG antibody levles to SARS-CoV-2 after 2 doses of Moderna or Pfizer vaccine was significantly higher than that of AstraZeneca vaccine (p<0.0001). SARS-CoV-2-IgG antibody levles increased progressively after injection, reaching high levels during 3-4 months after the first or second dose. They then gradually decreased over the following months. Conclusion: IgG antibody concentrations against SRAS-CoV-2 obtained after vaccination with Moderna or Pfizer were higher than those obtained after vaccination with AstraZeneca. Serum antibody concentrations in subjects decreased over time, suggesting the need for annual vaccine booster doses.
Article Details
References
2. Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC, Cabrera E, Hernández-Reyes Y, Hernández-Fernaud JR et al (2021) The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem Biophys Res Commun 543: 45-49.
3. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21(6): 803-812.
4. World Health Organization COVID-19 vaccine tracker (https://covid19.trackvaccines.org/agency/ who/). WHO 2022.
5. Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D et al (2021) Mini review immunological consequences of immunization with COVID-19 mRNA vaccines: Preliminary results. Front Immunol 12: 657711.
6. Chen M, Qin R, Jiang M, Yang Z, Wen W, Li J (2021) Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. Int J Infect Dis 104: 415-422.
7. Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al (2022) Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. 13.
8. Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G et al (2022) Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. Front Immunol 13: 850987.
9. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al (2021) Efficacy and safety of the mrna-1273 sars-cov-2 vaccine. N Engl J Med 384(5): 403-416.
10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 caccine. N Engl J Med 383(27): 2603-2615.
11. Knoll MD, Wonodi C (2021) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 397(10269): 72-74.
12. Prevention CfDCa (2021) Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity.
13. Stephen J, Thomas EDMJ, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbini, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper (2021) Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. medRxiv 2021.07.28.21261159; doi: https://doi.org/10.1101/2021.07.28.21261159.
14. Castiglione F, Deb D, Srivastava AP, Liò P, Liso A (2021) From infection to immunity: Understanding the response to SARS-CoV2 through in-silico modeling. Front Immunol. 2021 Sep 7;12:646972. doi: 10.3389/fimmu.2021.646972.
Article Sidebar
